FDA addresses use of remote interactive evaluations in post-pandemic era
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyComplianceMedical DevicesNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy